TY - JOUR
T1 - Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy
T2 - Report from the registry data in Japan
AU - Goto, Daisuke
AU - Kinugawa, Shintaro
AU - Hamaguchi, Sanae
AU - Sakakibara, Mamoru
AU - Tsuchihashi-Makaya, Miyuki
AU - Yokota, Takashi
AU - Yamada, Satoshi
AU - Yokoshiki, Hisashi
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
The JCARE-CARD investigators and participating cardiologists are listed in the Appendix of our previous publication [13] . This study could not have been carried out without the help, cooperation, and support of the cardiologists in the survey institutions. We thank them for allowing us to obtain the data. The JCARE-CARD was supported by the Japanese Circulation Society and the Japanese Society of Heart Failure and by grants from Health Sciences Research Grants from the Japanese Ministry of Health, Labor and Welfare (Comprehensive Research on Cardiovascular Diseases), the Japan Heart Foundation , and Japan Arteriosclerosis Prevention Fund .
PY - 2013/1
Y1 - 2013/1
N2 - Background: A subset of patients with hypertrophic cardiomyopathy (HCM) has been reported to progress into dilated-HCM (D-HCM), characterized by left ventricular (LV) systolic dysfunction and cavity dilatation, resembling idiopathic dilated cardiomyopathy (DCM). We compared the characteristics, treatments, and outcomes in patients with heart failure (HF) due to D-HCM vs. DCM by using national registry data in Japan. Methods and results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) is a prospective observational study of patients hospitalized due to worsening HF with an average of 2.2 years of follow-up. Patients with D-HCM (n=. 41) were more likely to be male, have prior stroke, atrial fibrillation, and sustained ventricular tachycardia or ventricular fibrillation compared with DCM (n=. 486). Echocardiography demonstrated that D-HCM patients had smaller LV end-systolic diameter, higher ejection fraction, and greater wall thickness. Treatments for HF including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, and spironolactone were similar between groups except for higher use of amiodarone, warfarin, and implantable cardioverter-defibrillator for D-HCM. Mortality was significantly higher in patients with D-HCM (29.7% vs. 14.4%; p<0.05). Sudden death tended to be higher also in D-HCM (8.1% vs. 2.6%; p=. 0.06), which, however, did not reach statistical significance. Conclusions: HF patients with D-HCM had higher mortality risk than those with DCM. Effective management strategies are critically needed to be established for D-HCM.
AB - Background: A subset of patients with hypertrophic cardiomyopathy (HCM) has been reported to progress into dilated-HCM (D-HCM), characterized by left ventricular (LV) systolic dysfunction and cavity dilatation, resembling idiopathic dilated cardiomyopathy (DCM). We compared the characteristics, treatments, and outcomes in patients with heart failure (HF) due to D-HCM vs. DCM by using national registry data in Japan. Methods and results: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) is a prospective observational study of patients hospitalized due to worsening HF with an average of 2.2 years of follow-up. Patients with D-HCM (n=. 41) were more likely to be male, have prior stroke, atrial fibrillation, and sustained ventricular tachycardia or ventricular fibrillation compared with DCM (n=. 486). Echocardiography demonstrated that D-HCM patients had smaller LV end-systolic diameter, higher ejection fraction, and greater wall thickness. Treatments for HF including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, and spironolactone were similar between groups except for higher use of amiodarone, warfarin, and implantable cardioverter-defibrillator for D-HCM. Mortality was significantly higher in patients with D-HCM (29.7% vs. 14.4%; p<0.05). Sudden death tended to be higher also in D-HCM (8.1% vs. 2.6%; p=. 0.06), which, however, did not reach statistical significance. Conclusions: HF patients with D-HCM had higher mortality risk than those with DCM. Effective management strategies are critically needed to be established for D-HCM.
UR - http://www.scopus.com/inward/record.url?scp=84872392985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872392985&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2012.08.010
DO - 10.1016/j.jjcc.2012.08.010
M3 - Article
C2 - 23078864
AN - SCOPUS:84872392985
VL - 61
SP - 65
EP - 70
JO - Journal of Cardiology
JF - Journal of Cardiology
SN - 0914-5087
IS - 1
ER -